December 12, 2012 - 8:32 a.m.
Gilead Sciences to Acquire YM BioSciences
Printer Friendly Version 
December 10, 2012 - 4:16 p.m.
Gilead Board Approves Two-for-One Stock Split
Printer Friendly Version 
December 03, 2012 - 4:31 p.m.
Gilead Sciences to Present at the NASDAQ OMX 29th Investor Program
Printer Friendly Version 
November 27, 2012 - 4:32 p.m.
European Commission Approves Viread® for HIV-1 Infection in Children and Adolescents and for Chronic Hepatitis B in Adolescents
Printer Friendly Version 
November 27, 2012 - 8:32 a.m.
Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients
Printer Friendly Version 
November 15, 2012 - 7:17 a.m.
Gilead’s Once-Daily Single Tablet Regimen Stribild™ Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naïve HIV Patients
Printer Friendly Version 
November 15, 2012 - 7:03 a.m.
Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naïve HIV Patients
Printer Friendly Version 
November 13, 2012 - 4:31 p.m.
Gilead Sciences to Present at the 2012 Credit Suisse Healthcare Conference on Wednesday, November 14
Printer Friendly Version 
November 10, 2012 - 9:04 a.m.
Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) for an Interferon-Free Regimen of Sofosbuvir (GS-7977), GS-5885 and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C Infected Patients
Printer Friendly Version 
October 31, 2012 - 8:02 a.m.
Gilead’s Once-Daily Novel Prodrug for the Treatment of HIV Meets 24-Week Primary Objective in Phase 2 Study
Printer Friendly Version 
October 23, 2012 - 4:04 p.m.
Gilead Sciences Announces Third Quarter 2012 Financial Results
Printer Friendly Version 
October 16, 2012 - 4:32 p.m.
Gilead Sciences to Release Third Quarter 2012 Financial Results on Tuesday, October 23, 2012
Printer Friendly Version 
September 18, 2012 - 4:31 p.m.
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Wednesday, September 19
Printer Friendly Version 
September 10, 2012 - 9:06 a.m.
Market Influences That Drive Equities Forward - Industry Report on Gilead Sciences, Inc. and Amgen Inc.
Printer Friendly Version 
September 05, 2012 - 4:31 p.m.
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12
Printer Friendly Version 
August 30, 2012 - 4:32 p.m.
Gilead Sciences to Present at Baird’s 2012 Healthcare Conference on Thursday, September 6
Printer Friendly Version 
August 30, 2012 - 9:05 a.m.
A Refreshing Outlook - Consensus Reports on Gilead Sciences, Inc. and Amgen Inc.
Printer Friendly Version 
August 27, 2012 - 5:12 p.m.
U.S. FDA Approves Gilead’s Stribild™, a Complete Once-Daily Single Tablet Regimen for Treatment-Naïve Adults with HIV-1 Infection
Printer Friendly Version 
August 02, 2012 - 8:32 a.m.
Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries
Printer Friendly Version 
July 26, 2012 - 4:06 p.m.
Gilead Sciences Announces Second Quarter 2012 Financial Results
Printer Friendly Version 
July 24, 2012 - 11:03 a.m.
Gilead’s HIV Integrase Inhibitor Elvitegravir Dosed Once Daily as Effective as Twice-Daily Raltegravir Over Two Years of Therapy in Pivotal Phase 3 Study
Printer Friendly Version 
July 24, 2012 - 11:03 a.m.
Gilead’s Once-Daily Single Tablet Regimen Complera® Maintains HIV Suppression Among Patients Switching From Protease Inhibitor-Based Regimens
Printer Friendly Version 
July 24, 2012 - 11:01 a.m.
Gilead’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study
Printer Friendly Version 
July 19, 2012 - 4:31 p.m.
Gilead Sciences to Release Second Quarter 2012 Financial Results on Thursday, July 26, 2012
Printer Friendly Version 
July 16, 2012 - 12:46 p.m.
U.S. Food and Drug Administration Approves Gilead’s Truvada® for Reducing the Risk of Acquiring HIV
Printer Friendly Version 
June 28, 2012 - 4:31 p.m.
Gilead Submits New Drug Application to U.S. FDA for Boosting Agent Cobicistat
Printer Friendly Version 
June 27, 2012 - 4:31 p.m.
Gilead Submits New Drug Application to U.S. FDA for HIV Integrase Inhibitor Elvitegravir for Treatment-Experienced Patients
Printer Friendly Version 
June 18, 2012 - 4:31 p.m.
European Medicines Agency Validates Gilead’s Marketing Application for Elvitegravir for Treatment of HIV Infection
Printer Friendly Version 
June 06, 2012 - 4:31 p.m.
Gilead Sciences to Present at the 32nd Annual William Blair & Company Growth Stock Conference on Wednesday, June 13
Printer Friendly Version 
June 06, 2012 - 8:31 a.m.
Gilead Sciences Appoints Two New Members to Health Policy Advisory Board
Printer Friendly Version 
May 29, 2012 - 4:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
May 23, 2012 - 4:06 p.m.
Gilead Files European Marketing Application for Boosting Agent Cobicistat
Printer Friendly Version 
May 11, 2012 - 3:32 p.m.
FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV
Printer Friendly Version 
May 10, 2012 - 8:37 p.m.
FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV
Printer Friendly Version 
May 08, 2012 - 4:32 p.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16
Printer Friendly Version 
May 01, 2012 - 6:02 p.m.
Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment of Chronic Lymphocytic Leukemia
Printer Friendly Version 
May 01, 2012 - 4:32 p.m.
Gilead Sciences to Present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8
Printer Friendly Version 
April 26, 2012 - 4:09 p.m.
Gilead Sciences Announces First Quarter 2012 Financial Results
Printer Friendly Version 
April 19, 2012 - 4:34 p.m.
Gilead Sciences to Release First Quarter 2012 Financial Results on Thursday, April 26, 2012
Printer Friendly Version 
April 19, 2012 - 4:19 p.m.
Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Na ïve Hepatitis C Patients
Printer Friendly Version 
April 19, 2012 - 5:03 a.m.
Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients
Printer Friendly Version 
April 19, 2012 - 5:02 a.m.
Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients
Printer Friendly Version 
April 18, 2012 - 7:33 a.m.
Gilead Sciences to Present New Hepatitis B and C Data at European Conference on Liver Disease This Week
Printer Friendly Version 
March 08, 2012 - 7:01 p.m.
Data Show Gilead’s Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study
Printer Friendly Version 
March 07, 2012 - 3:01 p.m.
Gilead’s Quad Single Tablet Regimen for HIV Non-Inferior to Atripla® in Pivotal Phase 3 Study
Printer Friendly Version 
March 06, 2012 - 4:36 p.m.
Gilead Sciences Quad Study 102 Results Conference Call on Wednesday, March 7, 2012
Printer Friendly Version 
March 06, 2012 - 4:31 p.m.
Gilead Sciences to Present at the Barclays Capital 2012 Global Healthcare Conference on Tuesday, March 13
Printer Friendly Version 
February 29, 2012 - 4:31 p.m.
Gilead Sciences to Present at the Cowen & Company 32nd Annual Health Care Conference on Wednesday, March 7
Printer Friendly Version 
February 24, 2012 - 4:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
February 17, 2012 - 6:02 a.m.
Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study
Printer Friendly Version 
February 13, 2012 - 7:26 p.m.
U.S. FDA Grants Priority Review for Truvada® for Reducing the Risk of Acquiring HIV Infection
Printer Friendly Version 
February 02, 2012 - 4:06 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2011 Financial Results
Printer Friendly Version 
January 26, 2012 - 4:31 p.m.
Gilead Sciences to Release Fourth Quarter and Year End 2011 Financial Results on Thursday, February 2, 2012
Printer Friendly Version 
January 24, 2012 - 4:06 p.m.
Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV
Printer Friendly Version 
January 18, 2012 - 7:16 p.m.
U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV
Printer Friendly Version 
January 18, 2012 - 4:41 p.m.
Roy D. Baynes, MD, PhD, to Join Gilead Sciences as Senior Vice President, Oncology Therapeutics
Printer Friendly Version 
January 17, 2012 - 5:01 p.m.
Gilead Sciences Completes Acquisition of Pharmasset, Inc.
Printer Friendly Version 
January 12, 2012 - 1:26 a.m.
Gilead Sciences Completes Tender Offer for All Outstanding Shares of Pharmasset, Inc.
Printer Friendly Version 
January 06, 2012 - 4:45 p.m.
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
Printer Friendly Version 
January 05, 2012 - 5:01 p.m.
Gilead Sciences to Present at the 30th Annual JPMorgan Healthcare Conference on Monday, January 9
Printer Friendly Version 
NASDAQ (US Dollar)
$69.37
 Stock is Up 0.54 (0.78%)
Data as of 02/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote